HALE DAVID F - 30 Jun 2021 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
30 Jun 2021
Net transactions value
-$17,428
Form type
4
Filing time
02 Jul 2021, 17:01:16 UTC
Previous filing
27 May 2021
Next filing
20 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Sale $17,428 -3,669 -0.51% $4.75 713,152 30 Jun 2021 By Hale BioPharma Ventures, LLC F1
holding ONCT Common Stock 18,346 30 Jun 2021 By Hale Trading Company
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were transferred to Oxford Finance LLC by Hale BioPharma Ventures, LLC in satisfaction of a pledge by Hale BioPharma Ventures, LLC which was previously disclosed by the Issuer.